What one share of Protagenic Therapeutics, Inc.\new holds
Protagenic Therapeutics, Inc.\new’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | $2.94 |
|---|---|
| Cash and investments | $0.31 |
| Book value | $0.95 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2015 | $0.00 | −$0.60 | $0.00 | −$0.23 | — | −$0.40 |
| 2016 | $0.00 | −$1.72 | — | — | — | $0.97 |
| 2017 | — | −$0.88 | — | — | — | $0.48 |
| 2018 | — | −$1.00 | — | — | — | −$0.08 |
| 2019 | — | −$0.68 | — | — | — | −$0.25 |
| 2020 | $0.00 | −$0.99 | — | — | — | −$0.44 |
| 2021 | $0.00 | −$1.23 | — | — | — | $2.31 |
| 2022 | $0.00 | −$0.82 | $0.00 | −$0.46 | — | $1.60 |
| 2023 | $0.00 | −$1.15 | $0.03 | −$0.89 | — | $0.83 |
| 2024 | $0.00 | −$1.13 | — | — | — | $0.14 |
| 2025 | $0.00 | −$0.67 | — | — | — | −$0.85 |
| 2026 | $0.00 | $0.59 | $0.00 | −$1.21 | — | $1.45 |
Common questions about Protagenic Therapeutics, Inc.\new
How much does one share of Protagenic Therapeutics, Inc.\new earn?
Over the last 12 months, each share of Protagenic Therapeutics, Inc.\new earned $2.94 of profit.
Does Protagenic Therapeutics, Inc.\new pay a dividend?
Protagenic Therapeutics, Inc.\new didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Protagenic Therapeutics, Inc.\new’s book value per share?
Protagenic Therapeutics, Inc.\new’s book value is $0.95 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Protagenic Therapeutics, Inc.\new have?
Each share of Protagenic Therapeutics, Inc.\new has $0.31 of cash and investments, as of June 30, 2026.
Has Protagenic Therapeutics, Inc.\new bought back shares?
Protagenic Therapeutics, Inc.\new’s share count rose about 41% from 2015 to 2026. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.